Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)

Authors

Evan Justin Walker, University of California
Christos Fountzilas, Roswell Park Comprehensive Cancer Center
Erkut Hasan Borazanci, HonorHealth Research Institute
Anthony F. Shields, Barbara Ann Karmanos Cancer Institute
James Thomas D'Olimpio, Clinical Research Alliance, Westbury, NY
J. Randolph Hecht, David Geffen School of Medicine at UCLA
Shou-Ching Tang, LSU Health Sciences Center - New OrleansFollow
Glenn Michelson, CG Pharmaceuticals Inc.
Lorna Liganor, CG Pharmaceuticals Inc.
Sangsook Ahn Cho, CG Pharmaceuticals Inc.
Andrew H. Ko, University of California

Document Type

Conference Proceeding

Publication Date

2-27-2024

Publication Title

Journal of Clinical Oncology

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

First Page

666

Volume

42

Comments

Abstract Number: 666

Recommended Citation

Walker, Evan Justin; Fountzilas, Christos; Borazanci, Erkut Hasan; Shields, Anthony F.; D'Olimpio, James Thomas; Hecht, J. Randolph; Tang, Shou-Ching; Michelson, Glenn; Liganor, Lorna; Cho, Sangsook Ahn; and Ko, Andrew H., "Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)" (2024). School of Medicine Faculty Publications. 2616.
https://digitalscholar.lsuhsc.edu/som_facpubs/2616
10.1200/JCO.2024.42.3_suppl.666